Review





Similar Products

94
MedChemExpress bay61 3606 hy76474
Bay61 3606 Hy76474, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bay+61+3606/BAY+61-3606/pm41951097-47-6-11
Average 94 stars, based on 1 article reviews
bay61 3606 hy76474 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

93
Selleck Chemicals bay
Tyrosine <t>kinase</t> <t>inhibitors</t> differentially modulate intra- and extracellular HCV infectious particle production . A , schematic overview of the experimental workflow. Huh-7.5 cells were seeded 1 day prior to infection (d-1), infected with HCVcc (MOI = 5) and treated with TKIs on day 0 (d0). After 24 h, the medium was refreshed and TKIs were re-administered (d1). After an additional 48 h of incubation (d3), culture supernatants and cell lysates were collected for TCID 50 assays and RT-qPCR. B , Quantification of extracellular HCV infectivity following TKI treatment. Naïve Huh-7.5 cells were inoculated with supernatants collected 72 h post-infection from TKI-treated cultures. Infectious titers were determined by TCID 50 assays using immunostaining for the HCV core protein. C , Extracellular HCV RNA was extracted and quantified by RT-qPCR. Viral RNA copy numbers were normalized to copies per microliter of supernatant. D , Comparison of intracellular and extracellular HCV titers following treatment with selected TKIs. Relative changes are shown for Bosutinib ( left ), Entospletinib ( middle ), and <t>BAY</t> 61-3606 ( right ) compared to untreated controls. Data are presented as mean ± SD from at least three independent biological replicates. Statistical significance was analyzed using One-way ANOVA followed by the Dunnett’s multiple comparisons test ( B , C ) or Mann-Whitney U test ( D ). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.
Bay, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bay+61+3606/BAY-61-3606/pmc12860343-254-10-12
Average 93 stars, based on 1 article reviews
bay - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

94
MedChemExpress syk inhibitor bay
Tyrosine <t>kinase</t> <t>inhibitors</t> differentially modulate intra- and extracellular HCV infectious particle production . A , schematic overview of the experimental workflow. Huh-7.5 cells were seeded 1 day prior to infection (d-1), infected with HCVcc (MOI = 5) and treated with TKIs on day 0 (d0). After 24 h, the medium was refreshed and TKIs were re-administered (d1). After an additional 48 h of incubation (d3), culture supernatants and cell lysates were collected for TCID 50 assays and RT-qPCR. B , Quantification of extracellular HCV infectivity following TKI treatment. Naïve Huh-7.5 cells were inoculated with supernatants collected 72 h post-infection from TKI-treated cultures. Infectious titers were determined by TCID 50 assays using immunostaining for the HCV core protein. C , Extracellular HCV RNA was extracted and quantified by RT-qPCR. Viral RNA copy numbers were normalized to copies per microliter of supernatant. D , Comparison of intracellular and extracellular HCV titers following treatment with selected TKIs. Relative changes are shown for Bosutinib ( left ), Entospletinib ( middle ), and <t>BAY</t> 61-3606 ( right ) compared to untreated controls. Data are presented as mean ± SD from at least three independent biological replicates. Statistical significance was analyzed using One-way ANOVA followed by the Dunnett’s multiple comparisons test ( B , C ) or Mann-Whitney U test ( D ). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.
Syk Inhibitor Bay, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bay+61+3606/BAY+61-3606/pm41398201-234-15-19
Average 94 stars, based on 1 article reviews
syk inhibitor bay - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

93
MedChemExpress syk inhibitor bay61 3606
Tyrosine <t>kinase</t> <t>inhibitors</t> differentially modulate intra- and extracellular HCV infectious particle production . A , schematic overview of the experimental workflow. Huh-7.5 cells were seeded 1 day prior to infection (d-1), infected with HCVcc (MOI = 5) and treated with TKIs on day 0 (d0). After 24 h, the medium was refreshed and TKIs were re-administered (d1). After an additional 48 h of incubation (d3), culture supernatants and cell lysates were collected for TCID 50 assays and RT-qPCR. B , Quantification of extracellular HCV infectivity following TKI treatment. Naïve Huh-7.5 cells were inoculated with supernatants collected 72 h post-infection from TKI-treated cultures. Infectious titers were determined by TCID 50 assays using immunostaining for the HCV core protein. C , Extracellular HCV RNA was extracted and quantified by RT-qPCR. Viral RNA copy numbers were normalized to copies per microliter of supernatant. D , Comparison of intracellular and extracellular HCV titers following treatment with selected TKIs. Relative changes are shown for Bosutinib ( left ), Entospletinib ( middle ), and <t>BAY</t> 61-3606 ( right ) compared to untreated controls. Data are presented as mean ± SD from at least three independent biological replicates. Statistical significance was analyzed using One-way ANOVA followed by the Dunnett’s multiple comparisons test ( B , C ) or Mann-Whitney U test ( D ). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.
Syk Inhibitor Bay61 3606, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bay+61+3606/BAY+61-3606+dihydrochloride/pmc12857633-425-0-3
Average 93 stars, based on 1 article reviews
syk inhibitor bay61 3606 - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

94
MedChemExpress 517 syk
Tyrosine <t>kinase</t> <t>inhibitors</t> differentially modulate intra- and extracellular HCV infectious particle production . A , schematic overview of the experimental workflow. Huh-7.5 cells were seeded 1 day prior to infection (d-1), infected with HCVcc (MOI = 5) and treated with TKIs on day 0 (d0). After 24 h, the medium was refreshed and TKIs were re-administered (d1). After an additional 48 h of incubation (d3), culture supernatants and cell lysates were collected for TCID 50 assays and RT-qPCR. B , Quantification of extracellular HCV infectivity following TKI treatment. Naïve Huh-7.5 cells were inoculated with supernatants collected 72 h post-infection from TKI-treated cultures. Infectious titers were determined by TCID 50 assays using immunostaining for the HCV core protein. C , Extracellular HCV RNA was extracted and quantified by RT-qPCR. Viral RNA copy numbers were normalized to copies per microliter of supernatant. D , Comparison of intracellular and extracellular HCV titers following treatment with selected TKIs. Relative changes are shown for Bosutinib ( left ), Entospletinib ( middle ), and <t>BAY</t> 61-3606 ( right ) compared to untreated controls. Data are presented as mean ± SD from at least three independent biological replicates. Statistical significance was analyzed using One-way ANOVA followed by the Dunnett’s multiple comparisons test ( B , C ) or Mann-Whitney U test ( D ). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.
517 Syk, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bay+61+3606/BAY+61-3606/pm41376156-242-0-10
Average 94 stars, based on 1 article reviews
517 syk - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

92
Santa Cruz Biotechnology bay 61 3606 hcl
Tyrosine <t>kinase</t> <t>inhibitors</t> differentially modulate intra- and extracellular HCV infectious particle production . A , schematic overview of the experimental workflow. Huh-7.5 cells were seeded 1 day prior to infection (d-1), infected with HCVcc (MOI = 5) and treated with TKIs on day 0 (d0). After 24 h, the medium was refreshed and TKIs were re-administered (d1). After an additional 48 h of incubation (d3), culture supernatants and cell lysates were collected for TCID 50 assays and RT-qPCR. B , Quantification of extracellular HCV infectivity following TKI treatment. Naïve Huh-7.5 cells were inoculated with supernatants collected 72 h post-infection from TKI-treated cultures. Infectious titers were determined by TCID 50 assays using immunostaining for the HCV core protein. C , Extracellular HCV RNA was extracted and quantified by RT-qPCR. Viral RNA copy numbers were normalized to copies per microliter of supernatant. D , Comparison of intracellular and extracellular HCV titers following treatment with selected TKIs. Relative changes are shown for Bosutinib ( left ), Entospletinib ( middle ), and <t>BAY</t> 61-3606 ( right ) compared to untreated controls. Data are presented as mean ± SD from at least three independent biological replicates. Statistical significance was analyzed using One-way ANOVA followed by the Dunnett’s multiple comparisons test ( B , C ) or Mann-Whitney U test ( D ). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.
Bay 61 3606 Hcl, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bay+61+3606/Syk+Inhibitor+IV%2C+BAY+61-3606+HCl/pmc12534707-35-3-9
Average 92 stars, based on 1 article reviews
bay 61 3606 hcl - by Bioz Stars, 2026-09
92/100 stars
  Buy from Supplier

93
Selleck Chemicals primary microglia
Tyrosine <t>kinase</t> <t>inhibitors</t> differentially modulate intra- and extracellular HCV infectious particle production . A , schematic overview of the experimental workflow. Huh-7.5 cells were seeded 1 day prior to infection (d-1), infected with HCVcc (MOI = 5) and treated with TKIs on day 0 (d0). After 24 h, the medium was refreshed and TKIs were re-administered (d1). After an additional 48 h of incubation (d3), culture supernatants and cell lysates were collected for TCID 50 assays and RT-qPCR. B , Quantification of extracellular HCV infectivity following TKI treatment. Naïve Huh-7.5 cells were inoculated with supernatants collected 72 h post-infection from TKI-treated cultures. Infectious titers were determined by TCID 50 assays using immunostaining for the HCV core protein. C , Extracellular HCV RNA was extracted and quantified by RT-qPCR. Viral RNA copy numbers were normalized to copies per microliter of supernatant. D , Comparison of intracellular and extracellular HCV titers following treatment with selected TKIs. Relative changes are shown for Bosutinib ( left ), Entospletinib ( middle ), and <t>BAY</t> 61-3606 ( right ) compared to untreated controls. Data are presented as mean ± SD from at least three independent biological replicates. Statistical significance was analyzed using One-way ANOVA followed by the Dunnett’s multiple comparisons test ( B , C ) or Mann-Whitney U test ( D ). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.
Primary Microglia, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bay+61+3606/BAY-61-3606/bio_rxiv__2025__05__30__657101-294-3-9
Average 93 stars, based on 1 article reviews
primary microglia - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

93
Selleck Chemicals bay 61 3606
Tyrosine <t>kinase</t> <t>inhibitors</t> differentially modulate intra- and extracellular HCV infectious particle production . A , schematic overview of the experimental workflow. Huh-7.5 cells were seeded 1 day prior to infection (d-1), infected with HCVcc (MOI = 5) and treated with TKIs on day 0 (d0). After 24 h, the medium was refreshed and TKIs were re-administered (d1). After an additional 48 h of incubation (d3), culture supernatants and cell lysates were collected for TCID 50 assays and RT-qPCR. B , Quantification of extracellular HCV infectivity following TKI treatment. Naïve Huh-7.5 cells were inoculated with supernatants collected 72 h post-infection from TKI-treated cultures. Infectious titers were determined by TCID 50 assays using immunostaining for the HCV core protein. C , Extracellular HCV RNA was extracted and quantified by RT-qPCR. Viral RNA copy numbers were normalized to copies per microliter of supernatant. D , Comparison of intracellular and extracellular HCV titers following treatment with selected TKIs. Relative changes are shown for Bosutinib ( left ), Entospletinib ( middle ), and <t>BAY</t> 61-3606 ( right ) compared to untreated controls. Data are presented as mean ± SD from at least three independent biological replicates. Statistical significance was analyzed using One-way ANOVA followed by the Dunnett’s multiple comparisons test ( B , C ) or Mann-Whitney U test ( D ). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.
Bay 61 3606, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bay+61+3606/BAY-61-3606/bio_rxiv__2025__05__30__657101-294-8-9
Average 93 stars, based on 1 article reviews
bay 61 3606 - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

Image Search Results


Tyrosine kinase inhibitors differentially modulate intra- and extracellular HCV infectious particle production . A , schematic overview of the experimental workflow. Huh-7.5 cells were seeded 1 day prior to infection (d-1), infected with HCVcc (MOI = 5) and treated with TKIs on day 0 (d0). After 24 h, the medium was refreshed and TKIs were re-administered (d1). After an additional 48 h of incubation (d3), culture supernatants and cell lysates were collected for TCID 50 assays and RT-qPCR. B , Quantification of extracellular HCV infectivity following TKI treatment. Naïve Huh-7.5 cells were inoculated with supernatants collected 72 h post-infection from TKI-treated cultures. Infectious titers were determined by TCID 50 assays using immunostaining for the HCV core protein. C , Extracellular HCV RNA was extracted and quantified by RT-qPCR. Viral RNA copy numbers were normalized to copies per microliter of supernatant. D , Comparison of intracellular and extracellular HCV titers following treatment with selected TKIs. Relative changes are shown for Bosutinib ( left ), Entospletinib ( middle ), and BAY 61-3606 ( right ) compared to untreated controls. Data are presented as mean ± SD from at least three independent biological replicates. Statistical significance was analyzed using One-way ANOVA followed by the Dunnett’s multiple comparisons test ( B , C ) or Mann-Whitney U test ( D ). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.

Journal: The Journal of Biological Chemistry

Article Title: Protein tyrosine kinase Src suppresses hepatitis C virus particle release through regulation of Ndrg1

doi: 10.1016/j.jbc.2025.111125

Figure Lengend Snippet: Tyrosine kinase inhibitors differentially modulate intra- and extracellular HCV infectious particle production . A , schematic overview of the experimental workflow. Huh-7.5 cells were seeded 1 day prior to infection (d-1), infected with HCVcc (MOI = 5) and treated with TKIs on day 0 (d0). After 24 h, the medium was refreshed and TKIs were re-administered (d1). After an additional 48 h of incubation (d3), culture supernatants and cell lysates were collected for TCID 50 assays and RT-qPCR. B , Quantification of extracellular HCV infectivity following TKI treatment. Naïve Huh-7.5 cells were inoculated with supernatants collected 72 h post-infection from TKI-treated cultures. Infectious titers were determined by TCID 50 assays using immunostaining for the HCV core protein. C , Extracellular HCV RNA was extracted and quantified by RT-qPCR. Viral RNA copy numbers were normalized to copies per microliter of supernatant. D , Comparison of intracellular and extracellular HCV titers following treatment with selected TKIs. Relative changes are shown for Bosutinib ( left ), Entospletinib ( middle ), and BAY 61-3606 ( right ) compared to untreated controls. Data are presented as mean ± SD from at least three independent biological replicates. Statistical significance was analyzed using One-way ANOVA followed by the Dunnett’s multiple comparisons test ( B , C ) or Mann-Whitney U test ( D ). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.

Article Snippet: In addition, two Syk kinase inhibitors, Entospletinib (Selleck, S7523) and BAY 61-3606 (Selleck, S7006), and the Egfr inhibitor Gefitinib (Funakoshi, CS-0124) were also included in the analysis.

Techniques: Infection, Incubation, Quantitative RT-PCR, Immunostaining, Comparison, MANN-WHITNEY

Effect of tyrosine kinase inhibitors on HCV infection efficiency and viral protein expression . A , Huh-7.5 cells were infected with HCVcc (MOI = 5) and treated with Bosutinib, Entospletinib, or BAY 61-3606 following the protocol described in A . At 72 h post-infection, cells were fixed and stained with an anti-core monoclonal antibody ( top panels ) and Hoechst to visualize nuclei ( bottom panels ). Scale bar, 100 μm. B , quantification of intracellular HCV RNA levels treated with the indicated inhibitors. Total RNA was extracted and analyzed by RT-qPCR. Data represent the relative expression normalized to untreated controls. C , immunoblot analysis of HCV NS3 and core protein expression. Detergent-soluble lysates were prepared from infected cells treated with the indicated inhibitors, separated by SDS-PAGE, and probed with anti-NS3, anti-core, and anti-actin antibodies. Densitometric quantification of NS3 and core protein levels relative to actin is shown in the right panels . Data are presented as mean ± SD from at least three independent biological replicates. Statistical significance was analyzed using Welch’s t test. ns, not significant. IB, immunoblot.

Journal: The Journal of Biological Chemistry

Article Title: Protein tyrosine kinase Src suppresses hepatitis C virus particle release through regulation of Ndrg1

doi: 10.1016/j.jbc.2025.111125

Figure Lengend Snippet: Effect of tyrosine kinase inhibitors on HCV infection efficiency and viral protein expression . A , Huh-7.5 cells were infected with HCVcc (MOI = 5) and treated with Bosutinib, Entospletinib, or BAY 61-3606 following the protocol described in A . At 72 h post-infection, cells were fixed and stained with an anti-core monoclonal antibody ( top panels ) and Hoechst to visualize nuclei ( bottom panels ). Scale bar, 100 μm. B , quantification of intracellular HCV RNA levels treated with the indicated inhibitors. Total RNA was extracted and analyzed by RT-qPCR. Data represent the relative expression normalized to untreated controls. C , immunoblot analysis of HCV NS3 and core protein expression. Detergent-soluble lysates were prepared from infected cells treated with the indicated inhibitors, separated by SDS-PAGE, and probed with anti-NS3, anti-core, and anti-actin antibodies. Densitometric quantification of NS3 and core protein levels relative to actin is shown in the right panels . Data are presented as mean ± SD from at least three independent biological replicates. Statistical significance was analyzed using Welch’s t test. ns, not significant. IB, immunoblot.

Article Snippet: In addition, two Syk kinase inhibitors, Entospletinib (Selleck, S7523) and BAY 61-3606 (Selleck, S7006), and the Egfr inhibitor Gefitinib (Funakoshi, CS-0124) were also included in the analysis.

Techniques: Infection, Expressing, Staining, Quantitative RT-PCR, Western Blot, SDS Page